Mark W. Kroll
Mark W. Kroll's purchase track record
Mark W. Kroll has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/10/2025 | HAE | $99K | -18.1% | -25.9% | +8.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Axon Gains Momentum After Multiple Federal Contracts. Axon Enterprise has secured new contracts from several U.S. federal agencies, boosting its federal sector momentum as the fiscal year ends. The company’s recent wins have drawn increased analyst coverage and investor interest. These developments come while the stock trades near its 52‑week low and shows a volume spike. The news highlights the firm’s expanding role in government security solutions.
Transaction History
| HAE | ▲ Buy | Grant | 2,538 | — | 7/24/2026 | View on chart |
| HAE | ▲ Buy | Open Market | 1,400 | $99K | 11/10/2025 | View on chart |
| HAE | ▲ Buy | Grant | 2,693 | — | 7/24/2025 | View on chart |
| HAE | ▲ Buy | Grant | 2,207 | — | 7/25/2024 | View on chart |
| HAE | ▲ Buy | Grant | 2,226 | — | 8/4/2023 | View on chart |
| AXON | ▲ Buy | Grant | 993 | $0 | 5/12/2023 | View on chart |
| AXON | ▼ Sell | Open Market | 92 | $20K | 3/7/2023 | View on chart |
| AXON | ▼ Sell | Open Market | 3,457 | $763K | 3/7/2023 | View on chart |
| HAE | ▼ Sell | Open Market | 8,016 | $591K | 8/15/2022 | View on chart |
| HAE | ▲ Buy | Grant | 2,730 | — | 8/5/2022 | View on chart |
| AXON | ▼ Sell | Open Market | 3,159 | $325K | 6/8/2022 | View on chart |
| AXON | ▲ Buy | Grant | 2,013 | $200K | 5/20/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Haemonetics Gets Price Target Hikes Amid Recent Stock Jump
Barrington Research and Mizuho both raised their price targets for Haemonetics to $140, maintaining Outperform ratings. This follows a recent 17.5% jump in the stock, which is now trading near its 52-week high. While some analysts note the current price may not be an ideal entry point, the firm's outlook has improved due to CSL Plasma developments.
Haemonetics Gets Price Target Hikes Amid Recent Stock Jump. Barrington Research and Mizuho both raised their price targets for Haemonetics to $140, maintaining Outperform ratings. This follows a recent 17.5% jump in the stock, which is now trading near its 52-week high. While some analysts note the current price may not be an ideal entry point, the firm's outlook has improved due to CSL Plasma developments.